Abatacept inhibits structural damage progression, as assessed by the genant-modified sharp scoring system, in Rheumatoid Arthritis (RA) patients with an inadequate response to Methotrexate (MTX): The aim (abatacept in inadequate responders to MTX) trial - A sub-analysis by disease duration

被引：0

作者：

Emery, P.

Westhovens, R.

Russell, A.

Moreland, L.

Kremer, J.

Becker, J-C.

Teng, J.

Genant, H. K.

机构：

[1] Univ Leeds, Leeds, W Yorkshire, England

[2] Katholieke Univ Leuven, Univ Hosp, Louvain, Belgium

[3] Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada

[4] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA

[5] Ctr Rheumatol, Albany, NY USA

[6] Bristol Myers Squibb Co, Princeton, NJ USA

[7] Bristol Myers Squibb Co, Pennington, NJ USA

[8] Univ Calif San Francisco, San Francisco, CA 94143 USA

来源：

RHEUMATOLOGY | 2006年 / 45卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：I41 / I42

页数：2

共 3 条

[1] METHODS OF ASSESSING RADIOGRAPHIC CHANGE IN RHEUMATOID-ARTHRITIS [J].

GENANT, HK .

AMERICAN JOURNAL OF MEDICINE, 1983, 75 (6A) :35-47

[2] Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition [J].

Genovese, MC ;

Becker, J ;

Schiff, M ;

Luggen, M ;

Sherrer, Y ;

Kremer, J ;

Birbara, C ;

Box, J ;

Natarajan, K ;

Nuamah, I ;

Li, T ;

Aranda, R ;

Hagerty, DT ;

Dougados, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (11) :1114-1123

[3] Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept - Twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial [J].

Kremer, JM ;

Dougados, M ;

Emery, P ;

Durez, P ;

Sibilia, J ;

Shergy, W ;

Steinfeld, S ;

Tindall, E ;

Becker, JC ;

Li, T ;

Nuamah, IF ;

Aranda, R ;

Moreland, LW .

ARTHRITIS AND RHEUMATISM, 2005, 52 (08) :2263-2271

← 1 →